11,857 Shares in Innoviva, Inc. $INVA Acquired by Vise Technologies Inc.

Vise Technologies Inc. acquired a new position in shares of Innoviva, Inc. (NASDAQ:INVA) in the 2nd quarter, HoldingsChannel.com reports. The fund acquired 11,857 shares of the biotechnology company’s stock, valued at approximately $238,000.

A number of other institutional investors also recently bought and sold shares of the company. Parallel Advisors LLC increased its position in shares of Innoviva by 157.5% in the second quarter. Parallel Advisors LLC now owns 1,849 shares of the biotechnology company’s stock valued at $37,000 after buying an additional 1,131 shares in the last quarter. Caitong International Asset Management Co. Ltd purchased a new position in Innoviva during the 1st quarter valued at about $56,000. Hantz Financial Services Inc. raised its position in Innoviva by 4,715.6% during the second quarter. Hantz Financial Services Inc. now owns 4,623 shares of the biotechnology company’s stock worth $93,000 after acquiring an additional 4,527 shares during the last quarter. GAMMA Investing LLC lifted its holdings in shares of Innoviva by 58.9% in the second quarter. GAMMA Investing LLC now owns 7,146 shares of the biotechnology company’s stock valued at $144,000 after purchasing an additional 2,648 shares in the last quarter. Finally, Bailard Inc. purchased a new stake in shares of Innoviva in the first quarter valued at about $189,000. 99.12% of the stock is currently owned by hedge funds and other institutional investors.

Innoviva Trading Down 1.3%

Shares of INVA opened at $21.97 on Tuesday. The stock has a fifty day moving average of $18.78 and a two-hundred day moving average of $19.40. The company has a debt-to-equity ratio of 0.36, a quick ratio of 2.44 and a current ratio of 2.64. The company has a market capitalization of $1.64 billion, a PE ratio of 70.87 and a beta of 0.42. Innoviva, Inc. has a fifty-two week low of $16.52 and a fifty-two week high of $22.76.

Innoviva (NASDAQ:INVA) last posted its quarterly earnings data on Wednesday, November 5th. The biotechnology company reported $1.08 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.46 by $0.62. The business had revenue of $107.80 million for the quarter, compared to analysts’ expectations of $91.31 million. Innoviva had a return on equity of 18.67% and a net margin of 10.44%. As a group, analysts forecast that Innoviva, Inc. will post 0.33 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on the stock. Oppenheimer initiated coverage on shares of Innoviva in a research note on Monday, August 11th. They set an “outperform” rating and a $45.00 price objective for the company. Cantor Fitzgerald raised their price target on Innoviva from $29.00 to $31.00 and gave the stock an “overweight” rating in a research report on Thursday, November 6th. Zacks Research cut Innoviva from a “strong-buy” rating to a “hold” rating in a report on Thursday, November 6th. Wall Street Zen raised Innoviva from a “buy” rating to a “strong-buy” rating in a research note on Saturday, October 25th. Finally, Weiss Ratings reiterated a “buy (b-)” rating on shares of Innoviva in a research report on Thursday. Five research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $38.60.

Innoviva Profile

Innoviva, Inc engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company’s products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.